Baron, A.JFlokstra-de Blok , B.M.JKerstjens, Huib AMKoopmans-Klein , GPrice, DavidSellink , A.ATsiligianni, IKocks, J.W.H2021-07-132021-07-132021-07-12Baron, A J, Flokstra-de Blok , B M J, Kerstjens, H AM, Koopmans-Klein , G, Price, D, Sellink , A A, Tsiligianni, I & Kocks, J W H 2021, 'High use of SABAs is associated with higher exacerbation rate in Dutch patients with asthma', Journal of Asthma and Allergy, vol. 2021, no. 14, pp. 851—861. https://doi.org/10.2147/JAA.S2929431178-6965https://hdl.handle.net/2164/16812Funding This study is funded by General Practitioners Research Institute and AstraZeneca Netherlands. The REALISE survey was funded by Mundipharma International Limited (Cambridge, UK). Acknowledgements We would like to thank the core study team, Thys van der Molen, Monica Fletcher, and David Price, the initial researchers of the REALISE study, for their advice on this study. We would like to thank Mundipharma Pharmaceuticals the Netherlands, for providing the data for this study.112141972engasthmashort acting beta2-agonistSABAprimary health careadverse effectsguidelinesR MedicineRJournal article10.2147/JAA.S29294314